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The link between microbial ﬂora and the shaping of immune responses is being increasingly appreciated, and
recent data have uncovered a role for recipient microbiota in the severity of graft-versus-host disease (GVHD).
The impact of donor microbiota on T cellemediated alloresponses and GVHD is not known, however. Using
multiple clinically relevant murine models, we analyzed the effect of donor microbiota on the severity of
GVHD induced by T cells from speciﬁc pathogen-free and germ-free donors, and found that donor microbiota
does not alter the expansion or differentiation of alloreactive T cells or the severity of GVHD.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Development of graft-versus-host disease (GVHD) after
allogeneic hematopoietic stem cell transplantation is the
major obstacle to the effective use of this potentially curative
therapy against many hematologic diseases, including
leukemia. The composition of the alloantigens and antigen-
presenting cells, inﬂammatory milieu, age, and several
other host-speciﬁc factors play important roles in the biology
of GVHD. These factors notwithstanding, the frequency of the
alloreactive donor T cells and their responses to alloantigens
are fundamental factors affecting the induction and severity
of GVHD [1].
Countless microbes colonize the intestine and skin and
form part of the host microbial ecology. Cross-talk of the
microbiota with various immune cell subsets of the host
immune system is known to modulate the immune
responses and affect autoimmunity, metabolic diseases, and
response to pathogens [2,3]. In line with this, previous and
recent data have uncovered a role for the host (recipient)
microbiome in the severity of GVHD. Studies in mice have
shown a reduction of GVHD with gut-decontaminating
antibiotics [4] and transplantation under germ-free (GF)
conditions [5]. Data have demonstrated shifts in the gut ﬂora
in GVHD recipients [6,7]. Furthermore, breaching of the
epithelial barriers and translocation of pathogen-associated
molecular patterns have been shown to enhance proin-
ﬂammatory cytokines released from damaged host tissue,
enhance donor T cell alloreactivity, and aggravate GVHD [8].
Resident microbiota plays key roles in the development and
maturation of T cells. CD4þ T cells from GF donors have been
found to cause colitis of similar or greater severity as T cells
from conventionally housed donors [9,10]. However, the
inﬂuence of the cross-talk in microbiota in shaping donoredgments on page 167.
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ously. Usingwell-characterizedmurinemodels,wecompared
the alloreactivity of T cells from GF donors and from
conventionally housed speciﬁc pathogen-free (SPF) donors to
induce GVHD, and found that donor microbiota does not
affect the severity of GVHD in hosts.
MATERIALS AND METHODS
Mice
SPF C57BL/6J (SPF-B6; H-2b) mice were purchased from Jackson Labo-
ratory (Bar Harbor, ME), and BALB/c (H-2d) and B6D2F1 (H-2b/d) mice were
purchased from the National Cancer Institute (Frederick, MD). GF C57BL6/J
(GF-B6) mice were maintained in a GF mouse facility at the University of
Michigan, where they were housed in soft-sided plastic isolators in which
they remained free of all bacteria, exogenous virus, fungi, and parasites until
just before euthanasia. All animal studies were performed in accordance
with protocols approved by the University of Michigan’s Committee on the
Use and Care of Animals.
Antibodies and Flow Cytometry
Our analyses used FITC-, PE-, PerCP-Cy5.5e, and APC-conjugated mAbs
to mouse CD4, CD8a, CD25, H-2Kb, H-2Kd, FoxP3 (all from eBioscience, San
Diego, CA), and anti-mouse TCR-b (BD Pharmingen, San Diego, CA). Flow
cytometry was performed as described previously [11], and the cells were
analyzed on an Accuri C6 ﬂow cytometer (BD Biosciences, San Jose, CA).
Bone Marrow Transplantation
Bone marrow (BM) transplantations (BMTs) were performed as
described previously [12]. In brief, recipient mice were irradiated (137Cs
source) with 8 Gy total body irradiation (BALB/c recipients) or 11 Gy total
body irradiation (B6D2F1 recipients) 1 day before BMT. BM cells were har-
vested from femurs and tibias of 7- to 8-week-old SPF-B6 mice and were
depleted of T cells using MACS CD90.2 microbeads and an LS column
(Miltenyi Biotec, Auburn, CA). T cells were harvested from the spleens of 7-
to 8-week-old SPF-B6 or GF-B6 mice. GF-B6 donor mice were euthanized
immediately after being transferred into the SPF environment, after which
T cells were isolated. BM cells and T cells were transplanted into allogeneic
experimental mice housed in sterilized microisolator cages under SPF
conditions and maintained on acidiﬁed water (pH < 3) for 3 weeks [13].
Survival was monitored daily, and clinical GVHD was assessed weekly [14].
Antibiotic Treatment
SPF C57BL/6J mice were provided with a cocktail of broad-spectrum oral
antibiotics, including metronidazole 0.5 mg/mL, neomycin 0.5 mg/mL,
ampicillin 0.5 mg/mL (Sigma-Aldrich, St. Louis, MO), and vancomycin 0.5
mg/mL, along with Splenda (McNeil Nutritional, Fort Washington, PA), in
autoclaved drinking water for 10-14 days before use as a source of donor
T cells.
Figure 1. GF mouse T cells respond against allogeneic stimulator, similar to SPF mouse T cells in vitro and in vivo. (A) CD90þ T cells were isolated from SPF-B6 mice
(left) or GF-B6 mice (right), and frequencies of CD4þFoxP3þ regulatory T cells were analyzed by ﬂow cytometry. (B) Isolated CD90þ T cells from SPF-B6 (ﬁlled bar) or
GF-B6 (open bar) mice were plated at 4  105/well in a 96-well ﬂat-bottomed plate and cocultured with different numbers of syngeneic B6 or allogeneic BALB/c
irradiated (30 Gy) spleen cells for 72 hours. 3H-thymidine (1 mCi/well) incorporation during last 6 hours of culture was measured. (C) Cytokine levels in the
supernatant of the 66-hour culture was determined by ELISA. (D and E) B6D2F1 recipients were irradiated (11 Gy) on day -1 and injected with allogeneic 5  106
SPF-B6 TCDBM cells plus 2  106 SPF-B6 CD90þ T cells (solid bar; n ¼ 3 for each time point) or allogeneic 5  106 SPF-B6 TCDBM cells plus 2  106 GF-B6 CD90þ T cells
(open bar; n ¼ 3 for each time point). Spleen cells and sera were collected from recipients on day 7 or day 14. (D) Spleen cells were counted; stained with antieH-2Kd,
-CD4, and -CD8 mAbs; and analyzed by ﬂow cytometry. Donor CD4 and CD8 T cell expansion was determined based on spleen cell count and the percentage of CD4
and CD8 positivity in gated (H-2Kd) cells. (E) Cytokine levels in the sera were determined by ELISA.
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Figure 2. GF mouse T cells and SPF mouse T cells induce GVHD to a similar extent. (A) BALB/c recipients were irradiated (8 Gy) on day -1 and injected with syngeneic
5  106 BALB/c BM cells (;; n ¼ 3), allogeneic 5  106 SPF C57BL/6J (SPF-B6) TCDBM cells plus 5  105 SPF-B6 CD90þ T cells (C; n ¼ 6), or allogeneic 5  106 SPF-B6
TCDBM cells plus 5  105 GF C57BL/6J (GF-B6) CD90þ T cells (B; n ¼ 6). Survival was monitored daily, and GVHD clinical score and body weight change were
monitored weekly. (B) B6D2F1 recipients were irradiated (11 Gy) on day -1 and injected with syngeneic 5  106 B6D2F1 BM cells (;; n ¼ 5), allogeneic 5  106 SPF-
B6 TCDBM cells plus 2  106 SPF-B6 CD90þ T cells (C; n ¼ 11), or allogeneic 5  106 SPF-B6 TCDBM cells plus 2  106 GF-B6 CD90þ T cells (B; n ¼ 11). Survival was
monitored daily, and GVHD clinical score and body weight change were monitored weekly. (C) B6D2F1 recipients were irradiated (11 Gy) on day -1 and injected with
allogeneic 5  106 SPF-B6 TCDBM cells plus 2  106 SPF-B6 CD90þ T cells (solid bar; n ¼ 3 for each time point) or allogeneic 5  106 SPF-B6 TCDBM cells plus 2  106
GF-B6 CD90þ T cells (open bar; n ¼ 3 for each time point). GVHD target tissue (small intestine and liver) were collected from recipients on day 7 or day 14.
Histopathological scores were determined for the small intestine (left) and liver (right). (D) Antibiotic treatment of donors does not mitigate GVHD in the recipients.
B6 donor mice were treated with a cocktail of oral antibiotics (open circles; n ¼ 10) or autoclaved water alone (solid circles; n ¼ 11), as described in Materials and
Methods. The donor T cells were harvested 10-14 days later and transplanted into allogeneic BALB/c or syngeneic B6 animals (inverted triangle) after conditioning
with 10 Gy along with TCDBM from SPF B6 donors. P ¼ not signiﬁcant. B versus C. Combined data from 2 similar experiments are shown.
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CD90þ T cells were isolated from spleen cells of SPF-B6 and GF-B6 mice
(4  105) and incubated with syngeneic (C57BL/6J) or allogeneic (BALB/c)
irradiated (30 Gy) spleen cells for 72 h. Proliferation was measured by the
incorporation of 3H-thymidine (1 mCi/well).
In Vivo Donor T Cell Expansion
B6D2F1 recipient mice were irradiated and transplanted with SPF-B6 T
celledepleted BM (TCDBM) and 2  106 CD90þ T cells from either SPF-B6 or
GF-B6 mice. On day 14 post-BMT, spleen cells were harvested and analyzed
for donor T cells (H-2Kd-) by ﬂow cytometry.
Cytokine Analysis
Levels of IFN-g, IL-5, IL-17A, and IL-10 in sera and culture supernatant
were determined by ELISA (BD Pharmingen) in accordance with the
manufacturer’s instructions.
Histology
Formalin-preserved gut and liver were embedded in parafﬁn, cut into
5-mm-thick sections, and stained with hematoxylin and eosin for histolog-
ical examination. Slides were coded and examined in a blinded fashion
by a pathologist (Chen Liu). A semiquantitative scoring system was used to
assess for the abnormalities known to be associated with GVHD [13].
Statistical Analysis
The Student t test was used for statistical analysis of in vitro data, and
the log-rank test was used for analysis of survival data. A P value <.05 was
considered statistically signiﬁcant.RESULTS AND DISCUSSION
We ﬁrst evaluated the in vitro alloresponses and regula-
tory T cell (Treg) frequencies of T cells harvested from the
spleens of GF mice. The CD90þ T cells from SPF-B6 and GF-B6
mice were analyzed for the frequency of CD4þFoxP3þ Tregs.
The frequency of Foxp3þ Tregs in the CD90þ T cell fraction
was similar in SPF-B6 and GF-B6 mice (Figure 1A). We next
analyzed the alloresponses of the T cells in vitro with mixed
leukocyte reaction (MLR) against allogeneic BALB/c irradi-
ated spleen cells at different responder/stimulator ratios.
SPF-B6 and GF-B6 T cells demonstrated equivalent prolifer-
ation, as well as similar levels of IFN-g, IL-5, and IL-17A
(signature cytokines for Th1, Th2, and Th17) in the super-
natants (Figure 1B and C).
We next evaluated the in vivo alloresponses of SPF-B6 and
GF-B6 T cells. Using an MHC-mismatched B6/B6D2F1
model, we performed allogeneic BMTwith donor Tcells from
either GF-B6 or SPF-B6 animals. The recipient sera and
spleens were harvested on day 7 or day 14 after BMT and
analyzed for allogeneic T cell expansion and differentiation.
Donor T cell expansion was similar in the allogeneic recipi-
ents for both CD4 (P ¼ .1220) and CD8 (P ¼ .0594) subsets
(Figure 1D). Serum levels of IFN-g, IL-5, IL-17A, and IL-10
(Th1, Th2, Th17, and Tr1) cytokines were also equivalent
(Figure 1E). These data indicate that the absence of cross-talk
with microbial ﬂora in donors does not alter T cell allor-
eactivity in vitro and in vivo.
To further determine the functional and clinical rele-
vance of the microbiome on donor T cell alloreactivity, we
analyzed the severity of GVHD induced by T cells isolated
from SPF-B6 mice and GF-B6 mice using well-established
MHC-mismatched B6/BALB/c GVHD model. We trans-
planted 5  105 T cells from either SPF-B6 or GF-B6 donors
along with 5  106 SPF-B6 TCDBM. The clinical severity and
mortality from GVHD was similar in the 2 groups (P ¼ .95;
Figure 2A). To rule out potential strain- and model-
dependent artifacts, we analyzed the induction of GVHD in
a second well-established B6/B6D2F1 model. We found no
statistically signiﬁcant difference in GVHD-mediatedmortality between the SPF-B6 and the GF-B6 allorecipient
mice (P ¼ .1061; Figure 2B). To further examine whether the
absence of donor microbiota might affect the ability of
donor T cells to cause differential GVHD target organ
damage, we analyzed GVHD-speciﬁc histopathology scores
of small intestine and liver from allogeneic B6D2F1 recipi-
ents on day 7 or day 14 after BMT (Figure 2C), and found no
signiﬁcant difference in GVHD severity. We next analyzed
whether treatment of SPF donor mice with a cocktail of
broad-spectrum oral antibiotics known to reduce and alter
gut microbial ﬂora would alter donor T cellemediated
GVHD mortality in the recipient animals [15,16]. Treat-
ment of B6 donor mice with broad-spectrum antibiotics
induced GVHD mortality at a rate similar to that seen in
control SPF donor mice. These data suggest that reducing
and altering the microbial ﬂora in the donors had no affect
on their T cell alloreactivity and induction of GVHD after
allogeneic BMT.
Emerging data demonstrate an important role for recip-
ient microbiota on the outcome of GVHD following alloge-
neic BMT from conventional donors. The role of donor
microbiota on the induction of alloreactivity and GVHD in
conventional recipients had not been studied previously,
however. We found similar magnitudes of proliferation,
differentiation, and GVHD in T cells from GF donors and
T cells from conventional or SPF mice. These data demon-
strate that in contrast to host microbiota, donor microbial
ﬂora do not affect the induction and severity of GVHD. Our
data are also consistent with the idea that after adoptive
transfer, the T cells from GF mice can induce pathogenic
autoimmune responses, such as colitis, and collectively
suggest either that donor microbial status does not affect
T cell response or that once transferred into conventional
settings, the previous lack of interaction with microbiota
does not inﬂuence subsequent responses [10].
Our donor mice were housed under stringent GF condi-
tions and fed normal chow; however, the potential lipo-
polysaccharide content of the diet was not controlled
for. Hrncir et al. [17] reported no signiﬁcant impact on
systemic immune phenotype regardless of lipopolysaccha-
ride contamination of chow in GF mice. It is possible that
speciﬁc components of or type of microbiota dysbiosis in
donors might have differential effects on the ability of donor
T cells to respond to alloantigens. As such, it is important to
note that our investigation did not address the impact of any
unique microbial genus on T cells in causing GVHD, but
instead analyzed the impact of a lack of all microbial ﬂora in
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